InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar)
Catalog #SIM0020
Clone:
Ustekinumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Ustekinumab making it ideal for research use. This Ustekinumab biosimilar reacts with human p40 also known as IL-12Ī². p40 is a 40 kDa subunit of IL-12 and IL-23. IL-12 is a heterodimeric cytokine composed of subunits IL-12Ī± p35 and IL-12Ī² p40. The p40 subunit of IL-12 also combines with p19, a protein that shows no biological activity by itself, to form IL-23. IL-12 is secreted by activated monocytes, macrophages, and dendritic cells while IL-23 is secreted by activated dendritic cells and epithelial cells. IL-12 plays roles in T lymphocyte differentiation, IFNĪ³ production, and NK cell cytotoxicity. The C17.8 antibody has been shown to neutralize both IL-12 and IL-23 bioactivity. Ustekinumab is used for the treatment of Crohnās disease, plaque psoriasis, and psoriatic arthritis.Specifications
Isotype | Human IgG1, Īŗ |
---|---|
Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
Immunogen | Human IL-12 p40 |
Reported Applications |
Functional assays |
Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
Sterility | 0.2 Āµm filtration |
Production | Purified from tissue culture supernatant in an animal free facility |
Purification | Protein A |
Molecular Weight | 150 kDa |
Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |